Drugs / SGN-CD47M
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03957096 | Jul 2019 → Sep 2020 | breast carcinoma, colorectal cancer, exocrine pancreatic carcinoma, gastric carcinoma +5 | Seagen Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SGN-CD47M | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03957096 ↗ |
| Route | Intravenous | “administered intravenously” NCT03957096 ↗ |